Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 underexpression
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab/relatlimab-rmbw
Sensitive: A1 - Approval
nivolumab / relatlimab-rmbw
Sensitive
:
A1
nivolumab/relatlimab-rmbw
Sensitive: A1 - Approval
nivolumab / relatlimab-rmbw
Sensitive
:
A1
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 underexpression
Lung Adenocarcinoma
PD-L1 underexpression
Lung Adenocarcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 underexpression
Squamous Cell Carcinoma of Head and Neck
PD-L1 underexpression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
nivolumab
Resistant: B - Late Trials
nivolumab
Resistant
:
B
nivolumab
Resistant: B - Late Trials
nivolumab
Resistant
:
B
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
PD-L1 underexpression
Gastric Adenocarcinoma
PD-L1 underexpression
Gastric Adenocarcinoma
Immunotherapy
Resistant: B - Late Trials
Immunotherapy
Resistant
:
B
Immunotherapy
Resistant: B - Late Trials
Immunotherapy
Resistant
:
B
PD-L1 underexpression
Esophageal Adenocarcinoma
PD-L1 underexpression
Esophageal Adenocarcinoma
Immunotherapy
Resistant: B - Late Trials
Immunotherapy
Resistant
:
B
Immunotherapy
Resistant: B - Late Trials
Immunotherapy
Resistant
:
B
PD-L1 underexpression
HER2 Positive Breast Cancer
PD-L1 underexpression
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
nivolumab + ipilimumab
Sensitive
:
C1
nivolumab + ipilimumab
Sensitive: C1 - Off-label
nivolumab + ipilimumab
Sensitive
:
C1
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
camrelizumab
Sensitive: C3 – Early Trials
camrelizumab
Sensitive
:
C3
camrelizumab
Sensitive: C3 – Early Trials
camrelizumab
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
ipilimumab + cemiplimab-rwlc
Sensitive: C3 – Early Trials
ipilimumab + cemiplimab-rwlc
Sensitive
:
C3
ipilimumab + cemiplimab-rwlc
Sensitive: C3 – Early Trials
ipilimumab + cemiplimab-rwlc
Sensitive
:
C3
PD-L1 underexpression
Urothelial Cancer
PD-L1 underexpression
Urothelial Cancer
nivolumab + IPI-549
Sensitive: C3 – Early Trials
nivolumab + IPI-549
Sensitive
:
C3
nivolumab + IPI-549
Sensitive: C3 – Early Trials
nivolumab + IPI-549
Sensitive
:
C3
PD-L1 underexpression
Mantle Cell Lymphoma
PD-L1 underexpression
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
PD-L1 underexpression
Cutaneous T-cell Lymphoma
PD-L1 underexpression
Cutaneous T-cell Lymphoma
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
durvalumab + lenalidomide
Sensitive
:
C3
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
durvalumab + lenalidomide
Sensitive
:
C3
PD-L1 underexpression
Triple Negative Breast Cancer
PD-L1 underexpression
Triple Negative Breast Cancer
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Acute Myelogenous Leukemia
PD-L1 underexpression
Acute Myelogenous Leukemia
XmAb14045
Sensitive: C3 – Early Trials
XmAb14045
Sensitive
:
C3
XmAb14045
Sensitive: C3 – Early Trials
XmAb14045
Sensitive
:
C3
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
PD-L1 underexpression
Squamous Cell Carcinoma of Head and Neck
PD-L1 underexpression
Squamous Cell Carcinoma of Head and Neck
cetuximab sarotalocan
Sensitive: C3 – Early Trials
cetuximab sarotalocan
Sensitive
:
C3
cetuximab sarotalocan
Sensitive: C3 – Early Trials
cetuximab sarotalocan
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
avelumab + VX15
Sensitive: C3 – Early Trials
avelumab + VX15
Sensitive
:
C3
avelumab + VX15
Sensitive: C3 – Early Trials
avelumab + VX15
Sensitive
:
C3
PD-L1 underexpression
Gastric Adenocarcinoma
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 underexpression
Colorectal Cancer
PD-L1 underexpression
Colorectal Cancer
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
atezolizumab + RG6180
Sensitive: C3 – Early Trials
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
PD-L1 underexpression
Renal Cell Carcinoma
PD-L1 underexpression
Renal Cell Carcinoma
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 underexpression
Hepatocellular Cancer
PD-L1 underexpression
Hepatocellular Cancer
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login